Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tiotropium bromide
Drug ID BADD_D02224
Description Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium].[A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]
Indications and Usage Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD.[L7084] A combination tiotropium and [olodaterol] metered inhalation spray is indicated for maintenance of COPD.[L7087] A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old.[L7090] A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.[L7093]
Marketing Status approved
ATC Code R03BB04
DrugBank ID DB01409
KEGG ID D01929
MeSH ID D000069447
PubChem ID 5487426
TTD Drug ID D0P1WA
NDC Product Code 0597-0075; 58175-0565; 50090-4248; 68180-964; 54239-011
UNII 0EB439235F
Synonyms Tiotropium Bromide | Bromide, Tiotropium | 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide | Tiotropium | Spiriva | BA 679 BR | 679 BR, BA | BR, BA 679 | BA-679 BR | BA679 BR
Chemical Information
Molecular Formula C19H22BrNO4S2
CAS Registry Number 136310-93-5
SMILES C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tonsillitis11.01.13.006; 22.07.03.008---
Type I hypersensitivity10.01.03.006---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002---
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001---
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Ventricular tachycardia02.03.04.010--
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Cardiac death02.03.04.015; 08.04.01.007---
Oropharyngeal candidiasis07.05.07.003; 11.03.03.006; 22.07.03.003---
Musculoskeletal discomfort15.03.04.001---
Angiopathy24.03.02.007---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Malnutrition14.03.02.004---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.002---
Urinary tract obstruction20.08.01.004--
Supraventricular tachyarrhythmia02.03.03.014---
Oropharyngeal discomfort07.05.05.008; 22.12.03.015---
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Candida infection11.03.03.021--
The 4th Page    First    Pre   4    Total 4 Pages